<DOC>
	<DOCNO>NCT02136940</DOCNO>
	<brief_summary>The objective parallel group study evaluate safety , tolerability efficacy AMA0076 reduction intraocular pressure subject primary open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Multiple Dose-parallel-group Study AMA0076 Patients With Primary Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<criteria>Adults 3085 year age . Diagnosis either POAG OHT eye . Not receive medication IOP , able stop medication washout period duration study without significant risk adverse consequence relate glaucomatous disease . Elevated IOP ( ≥ 24 ≤ 33 mm Hg 8 AM ≥ 21 ≤ 33 mm Hg 10 AM Screening Two visit Baseline visit one eye treatment [ washout phase subject receive ocular hypotensive therapy ] ) . Ophthalmic exclusion criterion : Uncontrolled intraocular hypertension define &gt; 33 mm Hg either eye either screening/baseline visit ( washout phase subject currently receive ocular hypotensive therapy ) . Receiving one medication IOP either eye time screen . Abnormal central corneal thickness . BCVA bad 20/200 ( logMAR 1.0 ) either eye Significant visual field loss . Acute angleclosure glaucoma appositional narrow anterior chamber angle either eye .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>